WNT7B: A Non-Code RNA Molecule, in Cancer, Neurodegenerative Diseases and Developmental Disorders

Target Name: WNT7B

NCBI ID: G7477

WNT7B

WNT7B: A Non-Code RNA Molecule, in Cancer, Neurodegenerative Diseases and Developmental Disorders

WNT7B, also known as WNT7B gene or WNT7B protein, is a non-coding RNA molecule that plays a crucial role in the development and maintenance of tissues and organs, including the nervous system and placenta. It is a transmembrane protein that is expressed in a variety of tissues, including fetal brain, liver, and heart, and has been implicated in several biological processes, including development, stem cell biology, and tissue repair.

Recent studies have identified WNT7B as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its expression has been observed in a wide range of diseases and conditions, making it a valuable tool for the study of these conditions.

One of the key features of WNT7B is its ability to self-organize into organized structures, such as neural networks and retinal arrays, during development. This self-organization is critical for the development and maintenance of tissues and organs, and is a key factor in the development of cancer.

Research has also shown that WNT7B is involved in several signaling pathways that are important for cell growth, differentiation, and survival. It has been shown to play a role in the development and progression of cancer, and has been identified as a potential therapeutic target for cancer treatment.

In addition to its role in cancer, WNT7B has also been linked to several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its expression has been observed in the brains of individuals with these conditions, and its overexpression has been shown to contribute to the development and progression of these diseases.

WNT7B has also been identified as a potential biomarker for these conditions, as its expression has been shown to be altered in individuals with neurodegenerative diseases. The use of WNT7B as a biomarker for neurodegenerative diseases has the potential to improve diagnosis and treatment, as researchers can use it as a target for drug development and therapy.

In addition to its role in neurodegenerative diseases, WNT7B has also been linked to several other conditions, including developmental disorders and tissue repair. Its expression has been observed in individuals with conditions such as Down syndrome, and its overexpression has been shown to contribute to the development and progression of these conditions.

The use of WNT7B as a potential drug target or biomarker for these conditions has the potential to improve treatment options and improve outcomes. For example, in individuals with Down syndrome, researchers have identified WNT7B as a potential target for drug development, with studies showing that Its overexpression is associated with increased neuronal death and decreased neural stem cell proliferation.

In conclusion, WNT7B is a non-coding RNA molecule that plays a crucial role in the development and maintenance of tissues and organs, including the nervous system and placenta. Its unique structure and function make it an attractive target for research into a wide range of conditions, including cancer, neurodegenerative diseases, and developmental disorders. As a potential drug target or biomarker, its study has the potential to improve treatment options and improve outcomes for a wide range of conditions.

Protein Name: Wnt Family Member 7B

Functions: Ligand for members of the frizzled family of seven transmembrane receptors that functions in the canonical Wnt/beta-catenin signaling pathway (PubMed:30026314). Required for normal fusion of the chorion and the allantois during placenta development (By similarity). Required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation (PubMed:30026314)

The "WNT7B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WNT7B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets